PhRMA readies suit over Florida’s newly authorized Canadian drug import plannews2024-01-08T21:49:37+00:00January 8th, 2024|Endpoints News|
Physicians are on board with mRNA vaccines, but worry about patient misinformation, survey findsnews2024-01-08T20:58:58+00:00January 8th, 2024|Endpoints News|
Senate health committee investigates inhaler manufacturers for high pricesnews2024-01-08T20:49:48+00:00January 8th, 2024|Endpoints News|
#JPM24: Elliott’s Marc Steinberg sees more healthcare investments for the sometimes-activist firm this yearnews2024-01-08T20:48:18+00:00January 8th, 2024|Endpoints News|
Vertex backs out of agreement with CRISPR Therapeutics for stem cell therapy candidate in diabetesnews2024-01-08T19:43:40+00:00January 8th, 2024|Endpoints News|
#JPM24: FDA’s Peter Marks says some secondary cancer cases after CAR-T therapy may be ‘causal,’ but benefits still outweigh risksnews2024-01-08T18:56:07+00:00January 8th, 2024|Endpoints News|
Updated: Novartis close to acquiring Cytokinetics after biotech’s PhIII heart disease win — WSJnews2024-01-08T18:36:31+00:00January 8th, 2024|Endpoints News|
Senti Bio cuts 37% of staff; Evotec pockets $25M milestone from BMS; Novartis buys SanRenonews2024-01-08T17:49:23+00:00January 8th, 2024|Endpoints News|
Veracyte to buy C2i Genomics for up to $95M, includes $70M upfrontnews2024-01-08T17:39:45+00:00January 8th, 2024|Endpoints News|
How health tech startups survived 2023 despite a 4-year funding lownews2024-01-08T17:00:45+00:00January 8th, 2024|Endpoints News|
